Table of Content
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Investments Along with Huge Funding for R&D of Genomics and Proteomics in Bio-pharmaceutical Industry
4.2.2 Rapid Technological Advancements in Peptide synthesizers Coupled by Strong Peptide Therapeutics Pipeline
4.3 Market Restraints
4.3.1 Issues Pertaining to Large-scale Peptide Synthesis and Lack of Robust Distribution Network
4.3.2 Challenges in Development of Proper Route of Administration of Peptide Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Technology
5.1.1 Solid-Phase
5.1.2 Liquid-Phase
5.1.3 Hybrid & Recombinant
5.2 Product
5.2.1 Equipment
5.2.2 Reagents & Consumables
5.2.3 Others
5.3 End-User
5.3.1 Pharmaceutical & Biotechnology Companies
5.3.2 Contract Development & Manufacturing Organization (CDMO)
5.3.3 Academic & Research Institutes
5.4 Geography
5.4.1 North America
5.4.1.1 United states
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AAPPTec
6.1.2 Anaspec Inc
6.1.3 Bachem Holding AG
6.1.4 Biotage AB
6.1.5 CEM Corporation
6.1.6 CSBio Company Inc
6.1.7 Gyros Protein Technologies AB
6.1.8 Merck KGaA
6.1.9 New England Peptide Inc
6.1.10 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS